Ambit Biosciences Announces Drug Screening Collaboration with GlaxoSmithKline.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Ambit (language) AMBIT - Algebraic Manipulation by Identity Translation (also claimed: "Acronym May Be Ignored Totally"). An early pattern-matching language, developed by C. Christensen of Massachusetts Computer Assocs in 1964, aimed at algebraic manipulation. Biosciences today announced that it has entered into an expanded kinase kinase /ki·nase/ (ki´nas) 1. a subclass of the transferases, comprising the enzymes that catalyze the transfer of a high-energy group from a donor (usually ATP) to an acceptor. 2. screening collaboration with GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ). Under the collaboration, Ambit will employ its proprietary kinase platform to profile kinase target specificity of selected GSK compounds, thereby accelerating the discovery and development of novel drug candidates. Ambit's groundbreaking kinase platform is a rapidly expanding panel of more than 170 quantitative, high-throughput kinase assays. "Our kinase platform enables Ambit and our partners to fundamentally improve and accelerate the process of identifying high-quality, small molecule kinase inhibitors. We are particularly proud of the GlaxoSmithKline collaboration because it is an expansion of our relationship that has been ongoing since 2003 and further validates our unique screening capability," said Scott Salka, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Ambit. "The earnings generated from our partnerships, including our existing multi-year collaboration with Roche, will support the continued development of Ambit's pipeline of drug candidates for the treatment of stroke and various cancers, the first of which we plan to advance into clinical trials during 2005." About Ambit Biosciences Ambit Biosciences is a privately-held biopharmaceutical company developing small molecule neuroprotectants for the treatment of stroke and other CNS See Continuous net settlement. CNS See continuous net settlement (CNS). disorders and kinase inhibitors for the treatment of cancers. Ambit plans to initiate clinical trials with its lead drug candidates for stroke in 2005 and oncology in early 2006. Ambit's proprietary technology, which has been validated through collaborations with Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Company, GlaxoSmithKline, Pfizer and Roche, provides an unprecedented ability to identify, characterize, and quantify protein-small molecule interactions. Ambit has raised a total of nearly $50 million from investors including Perseus-Soros Biopharmaceutical Fund, Forward Ventures, Roche, Avalon Ventures, and GIMV NV. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion